School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing 10029, China.
Liver Disease Branch, Shandong Hospital of Traditional Chinese Medicine, Jinan 250013, China.
J Tradit Chin Med. 2023 Feb;43(1):188-197. doi: 10.19852/j.cnki.jtcm.20221013.001.
To explore the core herbs of two illustrious senior Traditional Chinese Medicine (TCM) Physicians for the treatment of liver cancer, and to further clarify the gene targets and pathway mechanisms of liver cancer that the core prescription (CP) may regulate.
We used the patient information of two illustrious senior TCM physicians from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine and the Affiliated Hospital of Capital Medical University as the database. The CP was analyzed using the community network algorithm. The pathway mechanism was analyzed using network pharmacology method. And the prognostic survival genes were identified using Single factor cox regression analysis. Integrative Pharmacology-based Research Platform of Traditional Chinese Medicine (TCMIP), Herb, Online Mendelian Inheritance in Man (OMIM), Genecards, Kyoto Encyclopedia of Genes and Genomes (KEGG), Genomic Data Commons (GDC), The Cancer Genome Atlas (TCGA), Gephi and R were used to mine CP, building a pathway network diagram. All the analyses were visualized.
We found that the CP consistes of Huangqi (), Danshen (), Shuihonghuazi (), Baihuasheshecao (), Banzhilian (), and Ezhu (), which were attributed to the two physicians respectively. The CP played an anti-cancer role through such pathways as signal transduction, energy metabolism, immune system and other pathways, covering a total of 112 pathways and 176 herb-disease-related genes. Fourteen genes have a significant impact on the prognosis and survival of liver cancer.
Based on the liver cancer cases of two illustrious senior TCM physicians, we obtained the CP through data mining. The CP may mainly exert anti-cancer effects by inhibiting inflammatory response, angiogenesis, and enhancing the body's immune response. We screened out 14 genes in the CP that may be related to the prognosis of liver cancer, and these genes may play an important regulatory role in the prognosis of liver cancer.
探索两位著名资深中医(TCM)医师治疗肝癌的核心草药,并进一步阐明核心处方(CP)可能调节的肝癌基因靶点和通路机制。
我们使用山东中医药大学附属医院和首都医科大学附属医院两位著名资深 TCM 医师的患者信息作为数据库。使用社区网络算法分析 CP。使用网络药理学方法分析通路机制。使用单因素 cox 回归分析鉴定预后生存基因。整合中药药理学平台(TCMIP)、草药、在线孟德尔遗传(OMIM)、基因卡片、京都基因与基因组百科全书(KEGG)、基因组数据共享(GDC)、癌症基因组图谱(TCGA)、Gephi 和 R 用于挖掘 CP,构建通路网络图。所有分析均可视化。
我们发现 CP 由黄芪()、丹参()、水红花子()、白花蛇舌草()、半枝莲()和莪术()组成,分别归因于两位医师。CP 通过信号转导、能量代谢、免疫系统等途径发挥抗癌作用,共涉及 112 条途径和 176 个草药-疾病相关基因。有 14 个基因对肝癌的预后和生存有显著影响。
基于两位资深 TCM 医师的肝癌病例,我们通过数据挖掘获得了 CP。CP 可能主要通过抑制炎症反应、血管生成和增强机体免疫反应发挥抗癌作用。我们筛选出 CP 中可能与肝癌预后相关的 14 个基因,这些基因可能在肝癌预后中发挥重要调节作用。